Shire PLC (NASDAQ:SHPG)‘s stock had its “outperform” rating reissued by equities researchers at Royal Bank Of Canada in a report released on Wednesday. They presently have a $213.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 40.59% from the company’s previous close.

A number of other equities research analysts have also commented on SHPG. Cantor Fitzgerald started coverage on shares of Shire PLC in a report on Friday, June 16th. They set an “overweight” rating and a $222.00 price objective on the stock. BidaskClub lowered shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Friday, June 16th. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a research report on Thursday, July 6th. ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a research report on Wednesday, July 12th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $220.91.

Shire PLC (SHPG) opened at 151.50 on Wednesday. The stock has a market capitalization of $45.12 billion, a PE ratio of 67.79 and a beta of 1.63. Shire PLC has a 52-week low of $139.36 and a 52-week high of $192.64. The firm’s 50-day moving average is $152.69 and its 200 day moving average is $165.51.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, equities analysts forecast that Shire PLC will post $14.93 earnings per share for the current year.

WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/11/shire-plc-shpg-receives-outperform-rating-from-royal-bank-of-canada.html.

Several hedge funds have recently made changes to their positions in the stock. Maverick Capital Ltd. boosted its holdings in shares of Shire PLC by 19.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares during the period. Glenview Capital Management LLC boosted its holdings in shares of Shire PLC by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Shire PLC by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Shire PLC by 14.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares during the period. 19.28% of the stock is owned by institutional investors and hedge funds.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.